# A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

> **NCT01114542** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 66 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT01114542
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-03
- **Primary completion:** 2010-08-10
- **Final completion:** 2010-08-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2017-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01114542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01114542, "A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01114542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*